Skip to content
Search

Latest Stories

NHS Pay Review Body should focus on the pay rates of pharmacists in bands 5-8: PDA

NHS Pay Review Body should focus on the pay rates of pharmacists in bands 5-8: PDA

It also highlighted several workforce challenges that have impacted the recruitment and retention of pharmacists across all areas of pharmacy practice.    

The Pharmacists' Defence Association (PDA) has submitted evidence to the NHS Pay Review Body (PRB), emphasising on the recruitment and retention of NHS pharmacists.


It has urged the PRB to help the NHS achieve two important objectives – ensuring that pharmacists can achieve well-rewarded and the service is viewed as an appealing alternative by student pharmacists.

The PDA suggested that for the NHS to remain competitive, the PRB should focus its pay approach on employees within Bands 5-8 this year.

It recognised that the last recommendation from the PRB was a “flat rate increase” and it left those working in the above-mentioned bands feeling “unhappy”, which led to the CSP taking strike action over pay for the first time in their history.

Consequently, it recommended that this year’s recommendations should be referred to and linked to the 2018 restructuring of the Agenda for Change (AfC) pay bands.

Paul Moloney, PDA Union National Officer said: “The PDA has become increasingly concerned that the Pay Review Body receives no submission specifically related to pharmacists employed under Agenda for Change terms and conditions and we wanted to change that.

“We have therefore produced evidence to show the urgency of ensuring that pharmacists are fairly renumerated for the work they do and acknowledging that for many the purchasing power of their income has fallen over successive years.”

“While we are not arguing for special treatment for our 7,000 members in hospitals, we make a strong case for the PRB to look specifically as the pay bands our members work in and use that analysis as the driving force for this year’s recommendation to government on NHS pay,” he added.

As of 31 December 2023, the General Pharmaceutical Council (GPhC) register listed 64,104 pharmacists, with 54,119 of them located in England.

The PDA highlighted that while the number of registered pharmacists continues to grow “several workforce challenges” have impacted the recruitment and retention of pharmacists across all areas of pharmacy practice.

The workforce-related issues included chronic understaffing, sub-standard working environments, the inability to exercise their professional judgement, an absence of protected training time and experiences of racism, violence and abuse.

According to the Pharmacy Workforce Race Equality Standard (PWRES) report published by NHS England in September 2023, pharmacy team members of Black, Asian and minority ethnic origin experience more “harassment, bullying and abuse, poorer career progression and greater experience of discrimination” than White pharmacy team members.

In a survey conducted by the PDA, around 77 per cent of hospital pharmacists revealed that they were looking to change their career or employment status in the next 12-18 months, citing pressure and mental health concerns and pay as the primary issues

Other concerns were burnout, workplace pressure (not enough resources, skill mix) and dissatisfaction (lack of reward, feeling undervalued and demotivated).

A small number of respondents (four per cent) identified bullying and harassment as their main concerns.

In December 2023, the PDA carried out a separate workforce temperature check of over 2,000 pharmacists working in all areas of practice and it was found that nearly one-third of respondents were looking to leave pharmacy altogether

Approximately two-third of them were required to undertake more non-clinical work due to a lack of support staffing.

Further, the representative body of pharmacists reported that many of its members have chosen to become locum pharmacists to help manage workplace stress and poor mental health.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less